. "4" . . "3" . "RIV/00179906:_____/10:10069979!RIV11-MZ0-00179906" . . . "Maintenance therapy with rituximab for non-Hodgkin's lymphoma - opportunities in 2010"@en . . . "Rituximab in combination with chemotherapy is considered a standard treatment approach for first line setting in most of non-Hodgkin's lymphomas. Although most patients can reach complete of partial remission after this treatment, about 30 % of patients with aggressive lymphoma and almost all patients with advanced stage indolent lymphomas inevitably develop a relaps. The maintenance therapy with anti-CD20 monoclonal antibody, rituximab, represents one of the options how to extend disease-free interval in lymphoma patients. The aim of this article is to summarize information about the rituximab maintenance therapy of lymphoma, with respect to the current approved indications as well as to future directions, including potentially risks of this approach."@en . . . "7"^^ . . "Udr\u017Eovac\u00ED l\u00E9\u010Dba rituximabem u ne-Hodgkinov\u00FDch lymfom\u016F - mo\u017Enosti v roce 2010"@cs . "Onkologie" . "Kombinace chemoterapie a rituximabu je v sou\u010Dasn\u00E9 dob\u011B standardn\u00ED l\u00E9\u010Dbou 1. linie v\u011Bt\u0161iny B-ne-Hodgkinov\u00FDch lymfom\u016F. P\u0159esto\u017Ee je u v\u011Bt\u0161iny pacient\u016F touto l\u00E9\u010Dbou dosa\u017Eeno kompletn\u00ED nebo parci\u00E1ln\u00ED remise, u cca 30 % pacient\u016F s agresivn\u00EDmi lymfomy a u v\u011Bt\u0161iny nemocn\u00FDch s pokro\u010Dil\u00FDmi stadii indolentn\u00EDch lymfom\u016F onemocn\u011Bn\u00ED n\u00E1sledn\u011B relabuje. Jednou z mo\u017Enost\u00ED, jak zajistit prodlou\u017Een\u00ED bezp\u0159\u00EDznakov\u00E9ho obdob\u00ED u pacient\u016F s lymfomy, je pod\u00E1v\u00E1n\u00ED udr\u017Eovac\u00ED terapie monoklon\u00E1ln\u00ED protil\u00E1tkou anti-CD20 - rituximabem. C\u00EDlem publikace je shrnout poznatky a mo\u017Enosti udr\u017Eovac\u00ED terapie lymfom\u016F rituximabem v roce 2010 u jednotliv\u00FDch histologick\u00FDch typ\u016F lymfom\u016F, a to jak z hlediska v sou\u010Dasn\u00E9 dob\u011B ji\u017E klinicky ov\u011B\u0159en\u00FDch indikac\u00ED, tak i v\u00FDhled\u016F do budoucna, v\u010Detn\u011B mo\u017En\u00FDch rizik t\u00E9to l\u00E9\u010Dby."@cs . "Belada, David" . "294116" . "Udr\u017Eovac\u00ED l\u00E9\u010Dba rituximabem u ne-Hodgkinov\u00FDch lymfom\u016F - mo\u017Enosti v roce 2010" . . "[3B41316B3D7F]" . . . "Maintenance therapy with rituximab for non-Hodgkin's lymphoma - opportunities in 2010"@en . "Kombinace chemoterapie a rituximabu je v sou\u010Dasn\u00E9 dob\u011B standardn\u00ED l\u00E9\u010Dbou 1. linie v\u011Bt\u0161iny B-ne-Hodgkinov\u00FDch lymfom\u016F. P\u0159esto\u017Ee je u v\u011Bt\u0161iny pacient\u016F touto l\u00E9\u010Dbou dosa\u017Eeno kompletn\u00ED nebo parci\u00E1ln\u00ED remise, u cca 30 % pacient\u016F s agresivn\u00EDmi lymfomy a u v\u011Bt\u0161iny nemocn\u00FDch s pokro\u010Dil\u00FDmi stadii indolentn\u00EDch lymfom\u016F onemocn\u011Bn\u00ED n\u00E1sledn\u011B relabuje. Jednou z mo\u017Enost\u00ED, jak zajistit prodlou\u017Een\u00ED bezp\u0159\u00EDznakov\u00E9ho obdob\u00ED u pacient\u016F s lymfomy, je pod\u00E1v\u00E1n\u00ED udr\u017Eovac\u00ED terapie monoklon\u00E1ln\u00ED protil\u00E1tkou anti-CD20 - rituximabem. C\u00EDlem publikace je shrnout poznatky a mo\u017Enosti udr\u017Eovac\u00ED terapie lymfom\u016F rituximabem v roce 2010 u jednotliv\u00FDch histologick\u00FDch typ\u016F lymfom\u016F, a to jak z hlediska v sou\u010Dasn\u00E9 dob\u011B ji\u017E klinicky ov\u011B\u0159en\u00FDch indikac\u00ED, tak i v\u00FDhled\u016F do budoucna, v\u010Detn\u011B mo\u017En\u00FDch rizik t\u00E9to l\u00E9\u010Dby." . "Udr\u017Eovac\u00ED l\u00E9\u010Dba rituximabem u ne-Hodgkinov\u00FDch lymfom\u016F - mo\u017Enosti v roce 2010"@cs . "1"^^ . . "1"^^ . . . "V, Z(MZ0FNHK2005)" . "RIV/00179906:_____/10:10069979" . "Udr\u017Eovac\u00ED l\u00E9\u010Dba rituximabem u ne-Hodgkinov\u00FDch lymfom\u016F - mo\u017Enosti v roce 2010" . "rituximab; maintenance therapy; lymphoma"@en . "CZ - \u010Cesk\u00E1 republika" . "1802-4475" . .